Valuation: Keymed Biosciences Inc.

Market Cap 19.43B 2.9B 2.59B 2.41B 2.19B 4.13B 279B 4.16B 29.11B 11.32B 142B 10.88B 10.65B 458B P/E 2026 *
24.1x
P/E 2027 * 1,357x
Enterprise Value 18.31B 2.73B 2.44B 2.27B 2.07B 3.89B 263B 3.92B 27.42B 10.67B 134B 10.25B 10.03B 431B EV / Sales 2026 *
10.9x
EV / Sales 2027 * 8.62x
Free-Float
74.84%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 52 2018-04-22
Corporate Officer/Principal 61 2021-03-02
Corporate Secretary - 2022-03-28
Director TitleAgeSince
Chairman 52 2018-04-22
Director/Board Member 61 2021-03-02
Director/Board Member 52 2018-06-20
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.96B
+4.16%+3.04%+49.37%+94.17% 74.16B
-0.37%-3.81%+19.51%+78.12% 57.39B
+1.63%-1.61%+3.16%+36.89% 47.64B
+0.72%+2.89%+345.61%+721.71% 44.29B
+2.29%-2.57%+28.77%+33.46% 42.5B
+1.41%-1.71%+4.70%+111.36% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.56%+4.53%+31.34%+26.92% 28.53B
+1.61%-0.92%-6.65%-10.64% 24.34B
Average +1.20%-0.59%+53.90%+127.34% 43.39B
Weighted average by Cap. +1.53%-0.84%+58.06%+136.55%

Financials

2026 *2027 *
Net sales 1.68B 251M 224M 208M 190M 357M 24.16B 360M 2.52B 980M 12.33B 942M 921M 39.63B 2.15B 320M 286M 266M 242M 456M 30.83B 459M 3.21B 1.25B 15.73B 1.2B 1.18B 50.57B
Net income 672M 100M 89.48M 83.36M 75.86M 143M 9.66B 144M 1.01B 392M 4.93B 377M 368M 15.85B -14.18M -2.11M -1.89M -1.76M -1.6M -3.01M -204M -3.03M -21.24M -8.26M -104M -7.94M -7.77M -334M
Net Debt -1.12B -167M -149M -139M -127M -239M -16.13B -240M -1.68B -654M -8.23B -629M -615M -26.46B -935M -139M -124M -116M -105M -199M -13.43B -200M -1.4B -545M -6.86B -524M -512M -22.04B
Logo Keymed Biosciences Inc.
KeyMed Biosciences Inc is a biotechnology company principally engaged in the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. The Company also focused on the research and development of pharmaceutical products. The Company's main products comprise CM310, CM326, CM313 and CM383, mainly used for treating various type II immunological diseases in adults, adolescents and children, including moderate-to-severe atopic dermatitis (AD), moderate-to-severe asthma, CRSwNP, AR and potentially COP. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company mainly conducts its businesses in the domestic market and overseas markets.
Employees
1,768
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
65.96CNY
Average target price
88.83CNY
Spread / Average Target
+34.68%

Quarterly revenue - Rate of surprise